Fjarde Ap Fonden Horizon Therapeutics Public LTD CO Transaction History

Fjarde Ap Fonden

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 23, 2023	SELL	$98.98 - $115.74 $376,124 - $439,812	-3,800 Reduced 4.56%	79,584 $9.21 Million
Q2 2023 Aug 02, 2023	BUY	$96.34 - $112.38 $163,778 - $191,046	1,700 Added 2.08%	83,384 $8.58 Million
Q1 2023 May 15, 2023	SELL	$107.32 - $113.5 $987,343 - $1.04 Million	-9,200 Reduced 10.12%	81,684 $8.91 Million
Q4 2022 Feb 14, 2023	SELL	$62.39 - $113.8 $99,824 - $182,080	-1,600 Reduced 1.73%	90,884 $10.3 Million
Q2 2022 Aug 11, 2022	BUY	$79.4 - $116.36 $1.29 Million - $1.89 Million	16,200 Added 21.24%	92,484 $7.38 Million
Q1 2022 May 13, 2022	BUY	$86.42 - $109.81 $378,865 - $481,407	4,384 Added 6.1%	76,284 $8.03 Million
Q4 2021 Feb 15, 2022	BUY	$98.56 - $119.91 $59,136 - $71,946	600 Added 0.84%	71,900 $7.75 Million
Q3 2021 Nov 15, 2021	SELL	$91.91 - $110.37 $248,157 - $297,999	-2,700 Reduced 3.65%	71,300 $7.81 Million
Q2 2021 Aug 12, 2021	SELL	$86.24 - $95.92 $379,456 - $422,048	-4,400 Reduced 5.61%	74,000 $6.93 Million
Q1 2021 May 17, 2021	SELL	$71.83 - $95.48 $50,281 - $66,836	-700 Reduced 0.88%	78,400 $7.22 Million
Q4 2020 Feb 12, 2021	BUY	$67.0 - $84.39 $5.3 Million - $6.68 Million	79,100 New	79,100 $5.79 Million

2.07M

20K

Ticker HZNP
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 230,384,000
Description
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines ...

Get notified when there are updates to the investment portfolio of Fjarde Ap Fonden , based on Form 13F filings with the SEC.

Stay updated on Fjarde Ap Fonden with notifications on news.